Introduction
Quinolones are used in medicine and veterinary practice for treatment of infectious diseases caused by enteric bacteria such as Escherichia coli. In recent years, a substantive increase in quinolone resistance in human and animal E. coli isolates has been observed. 1, 2 The most frequent mechanism of resistance to quinolones in E. coli includes alterations in genes that encode subunits of the quinolone targets DNA gyrase (in gyrA and gyrB genes) and topoisomerase IV (in parC and parE). [2] [3] [4] These alterations involve mainly mutations located in the quinolone resistance-determining region (QRDR) of the gyrA gene and its homologous region of the parC gene. 3, 5, 6 In contrast, mutations in gyrB and parE genes are of minor importance and are rare contributors to quinolone resistance. 4, 7 Other mechanisms of resistance, such as efflux pump systems or modifications of porins, can decrease susceptibility to quinolones. 2, 5, 7, 8 Most of the studies on mechanisms of quinolone resistance in E. coli have been performed in human clinical strains and very few studies have focused on strains from animals or foods. 2, 7 In this study, mutations in gyrA, parC and gyrB have been analysed in nalidixic acid-resistant (NAL R ) E. coli strains from food products, humans and animals.
Materials and methods
Eighty unrelated NAL R E. coli strains (MIC ≥ 32 mg/L) recovered from different sources 1 enzymes XbaI and SfiI (data not shown). The origins of these strains were: food products of animal origin (23), faecal samples from healthy animals (broilers, 27; pigs, nine; dogs, six) and human faecal samples (in-and outpatients, 13; healthy volunteers, two). Thirteen nalidixic acid-susceptible (NAL S ) E. coli (animals, seven; foods, two; humans, four) were also included. 1 The MICs of nalidixic acid and ciprofloxacin were determined by an agar dilution method in Mueller-Hinton agar, according to NCCLS guidelines.
Mechanisms of resistance to quinolones
Detection of mutations in the QRDR of the gyrA gene, as well as in the analogous region of the parC gene, was performed in the 80 NAL R and 13 NAL S strains by PCR. 4, 6 Amplified fragments were purified (Qiagen), and both strands were automatically sequenced (ABI 310, Applied Biosystems, Madrid, Spain) using the same set of primers as for the PCR. Mutations in the gyrB gene were also analysed by sequencing specific amplicons in 18 NAL R strains. 9 Sequences obtained were compared with those previously reported for gyrA (GenBank accession no. X06373), gyrB (X04341) and parC genes (M58408 with the modification included in L22025). Table 1 shows the nalidixic acid and ciprofloxacin MICs for the 93 E. coli strains (80 NAL R , 13 NAL S ) and the deduced amino acid changes in the QRDR of GyrA and ParC proteins.
Results and discussion
No amino acid changes were detected in GyrA or ParC proteins in the 13 NAL S isolates, whereas at least one amino acid substitution in the GyrA protein (position 83 and/or 87) was detected in all NAL R strains. A single amino acid substitution in the QRDR of GyrA protein was detected in 62 NAL R strains (ciprofloxacin MIC range 0.03-4 mg/L). The substitutions were as follows (number of strains): Ser-83→Leu (55), Ser-83→Val (one), Ser-83→Ala (one), Asp-87→Asn (two), Asp-87→Tyr (two) and Asp-87→Gly (one). Double changes in the GyrA protein were detected in the remaining 18 NAL R strains (ciprofloxacin MIC range 4-64 mg/L). All exhibited the Ser-83→Leu substitution, and an additional substitution of Asp-87 for Asn (15 strains), Tyr (two) or His (one). The change Ser-83→Leu was the substitution most frequently identified, as previously reported. 2, 3, 6, 9 To our knowledge, this is the first report of the Ser-83→Val substitution in the GyrA protein of E. coli strains as a spontaneous mutation, and the Ser-83→Ala substitution in a strain of food origin. Tavio et al. 10 reported the Ser-83→Ala change in a human E. coli clinical isolate and also described the Ser-83→Val substitution in an in vitro mutant selected under antibiotic pressure. In respect of changes in position 87, our results revealed that the Asp-87→Tyr and Asp-87→Gly single substitutions in the GyrA protein were associated with a lower ciprofloxacin MIC (0.06 mg/L) than the Asp-87→Asn change (MICs 0.25-0.5 mg/L) ( Table 1 ). The substitutions of Ser-83 for Leu, Ala or Val have resulted not only in the loss of the hydroxyl group of serine and thus the ability to form hydrogen bonds, but also in the replacement by an aliphatic chain. All the changes in Asp-87 for Asn, Tyr, Gly or His involve the loss of a negatively charged amino acid. 6 These changes suggest that the ability to form hydrogen bonds and the negative charge at these positions seem to be important for quinolone interactions with the DNA gyrase-DNA complex.
Analysis inside the QRDR of the gyrA sequences of all 93 strains (NAL R and NAL S ), in comparison with the gyrA sequence previously reported (GenBank accession no. X06373), revealed five different patterns (A-E), according to silent mutations identified at positions 255, 261, 267, 273, 282 and 300 ( Table 2 ). All strains exhibited a T→C transition at nucleotide 267. Mutations at positions 261 and 282 have not been reported previously. Table 2 shows the relationship between silent mutation patterns and amino acid substitutions in the GyrA protein.
A single amino acid change in the QRDR of the ParC protein was found in 26 NAL R strains, which also showed changes in the GyrA protein (ciprofloxacin MIC range 0.5-64 mg/L) ( Table 1 ). The amino acid substitutions were as follows: Ser-80→Ile (16), Ser-80→Arg (seven), Glu-84→Lys (two) and Glu-84→Val (one). To our knowledge this is the first time Glu-84→Val has been described as a single substitution in the ParC protein. A double amino acid change in the ParC protein (Ser-80→Ile and Glu-84→Gly) reported previously 5 was detected in one strain. In respect of amino acid substitutions in the ParC protein, the ability to form hydrogen bonds is reduced when Ser-80 is substituted for Ile or Arg, whereas the change of Glu for Lys, Val or Gly at position 84 involves the loss of a negative charge. These observations are similar to those for the GyrA protein.
Two substitutions outside the QRDR of the ParC protein (Ala-56→Thr and Ser-57→Thr) were identified in two strains. The substitution Ala-56→Thr was detected in one NAL R E. coli from a pig (ciprofloxacin MIC 0.5 mg/L) and the Ser-57→Thr change in one strain from food (E. coli Co7). This strain also presented a double amino acid substitution in the GyrA protein (Ser-83→Leu + Asp-87→Tyr) and a single amino acid change in the ParC protein (Glu-84→Lys) ( Table 1 ). In addition, E. coli Co7 also showed a total of 14 different silent mutations inside the QRDR of the parC gene.
Analysis inside the QRDR of the parC sequences of all 93 strains, in comparison with the parC sequence previously reported (GenBank accession nos M58408 and L22025) revealed six different patterns (from I to VI) according to the silent mutations identified at positions 240, 243, 273 and 321 (Table 2) . No silent mutations were found in the 22 strains included in pattern I, whereas the remaining 71 strains presented a transition (a guanine instead of an adenine) at nucleotide 273. Table 2 shows the relationship between silent mutation patterns and amino acid substitutions in ParC.
No changes were observed in the GyrB protein of the 18 NAL R strains.
A correlation between the number of changes in GyrA and ParC proteins and the level of quinolone resistance in E. coli strains was observed. This is in accordance with previous observations. 4, 5, 7 None of the NAL S E. coli showed amino acid changes either in GyrA or in ParC. A single substitution in the GyrA protein was associated with a decrease in susceptibility to ciprofloxacin (MIC 0.03-1 mg/L) and two amino acid changes (one in GyrA and the other in ParC) with a low level of resistance to ciprofloxacin (2-4 mg/L). Three amino acid substitutions (two in GyrA and one in ParC) were associated with a moderate or high level of ciprofloxacin resistance (8-32 mg/L), and four substitutions (two in GyrA and two in ParC) with the highest ciprofloxacin MIC observed (64 mg/L). Several strains did not follow the above schedule (Table 1) : six strains with ciprofloxacin MICs ranging from 0.5 to 1 mg/L showed two amino acid changes (one in GyrA and other in ParC), and one strain with a ciprofloxacin MIC of 4 mg/L had three amino acid changes (two in GyrA and one in ParC proteins). MICs of all seven strains could be explained by increasing drug permeability. 4 However, in contrast to these Table 1 . Amino acid changes in the QRDR of GyrA and ParC proteins in 93 E. coli strains (80 NAL R and 13 NAL S ) of different origins and the corresponding nalidixic acid and ciprofloxacin MICs B, broiler; F, food product; P, pig; D, dog; H, human; NAL, nalidixic acid; CIP, ciprofloxacin; wild, no amino acid changes. a The deduced GyrA amino acid sequence was compared with that previously reported (GenBank accession no. X06373). b The deduced ParC amino acid sequence was compared with that previously reported (GenBank accession no. M58408 with the modifications included in L22025). c One of these strains showed a change outside the QRDR of ParC (Ala-56→Thr). d This strain (E. coli Co7) showed a change outside the QRDR of ParC (Ser-57→Thr). observations, three amino acid changes were detected in one E. coli strain with a ciprofloxacin MIC of 64 mg/L. The presence of active efflux pumps or mutations that affect regulatory loci (e.g. mar and sox) might be associated with this high ciprofloxacin MIC. 2, 5, 8 These other mechanisms might also be responsible for the wide range of ciprofloxacin MICs (4-64 mg/L) detected in strains that show the same amino acid substitutions in GyrA (Ser-83→Leu + Asp-87→Asn) and in ParC proteins (Ser-80→Ile).
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In the present study, a large variety of amino acid changes in GyrA and ParC proteins were detected in the NAL R E. coli strains of different origins. A correlation was found between the number of changes in the QRDR of GyrA and ParC proteins and the level of quinolone resistance of the E. coli strains.
